Moe Alsumidaie

In this Q&A, David Esposito, CEO of ONL Therapeutics provides a glimpse into the company's mission, challenges, and strategies associated with clinical trials.

In this Q&A, Dodd speaks about GeoVax's vaccine development strategy, clinical trials, and approach to serving patient populations often overlooked by conventional vaccines.

Insights from Clinical Quality Oversight Forum.

Jeff Liter, CEO of Luminary Therapeutics discusses the company's unique approach in the fast-evolving landscape of cancer treatment.

Nathalie Dubois-Stringfellow, Sangamo’s chief development officer discusses the company's diverse clinical programs, strategic collaborations, including a partnership with Pfizer, and the crucial role of patient safety.

How retail pharmacies can harness their resources to improve clinical trial access.

In this Q&A, Craig Lipset offers additional insights following the announcement that CVS will be closing its clinical trial services business by the end of the year.

In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors.

The journey of CVS Health’s clinical trials unit serves as a speculative case study, reminding us that venturing into new market areas, even for established companies, necessitates a careful evaluation of strategic fit, competition, infrastructure, financial constraints, and industry trends.

Tiffany Chow, MD, a specialist in behavioral neurology and senior medical director at Alector, discusses the unique challenges of designing clinical trials for frontotemporal dementia.

Presentation at SCOPE 2023 highlights tools such as interactive schedules and benchmarked data which can increase patient centricity.

Merck presentation at SCOPE 2023 highlights company’s AI-assisted data validation approach.

John R. Sims, senior vice president and head of global development, and Dawn A. Brooks, director of clinical development; both with Eli Lilly discuss the design of the TRAILBLAZER-ALZ program.

A point-of-view summary of a pharmaceutical presentation.

A summary of this year’s key topics and discussions.

Despite benefits of industry leaders' involvement, patient participation in clinical trials remain low.

Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis.

Challenges and strategies for improving representation.

Craig Coleman, PharmD, Professor at the University of Connecticut, and the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) study's principal investigator discusses the ins and outs of the study.

Artem Andrianov, CEO of Cyntegrity, discusses the launch of his company's new tool; the Drug Interaction Visualizer.

Recent industry advancements such as DCTs, AI, and machine learning are shaping the future of clinical trials.

Latest recommendation places great emphasis on patients.

Gillian Livock, SVP & general manager, customer engagement at Medable and Noolie Gregory, VP of DCT operations at Syneos Health discuss how combining technology with clinical operations delivers better data and clinical trial patient oversight.

Tim Bray, chief sourcing and training officer at Virb discusses how CROs and sponsors can mitigate risks by onboarding CRAs with less experience.

Michelle Webb, vice president of the WCG Avoca Quality Consortium, discusses her perspectives on FDA's revised overview of inspection activities.

Insights from second annual DTRA meeting indicate DCTs are here to stay.

Strong shift to DCTs, regulatory changes, and increased focus on diversity among main industry talking points in 2022.

Kenneth Koblan, PhD, chief scientific officer at Sunovion, discusses novel therapy development and clinical trial challenges in mental health.

Nabil Chehab, medical affairs head of lung cancer franchise at AstraZeneca, discuss strategies used in the Phase III AEGEAN trial for treating non-small lung cancer (NSCLC).